KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Consolidated Net Income (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Consolidated Net Income for 13 consecutive years, with -$4.4 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 64.55% to -$4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$34.2 million through Dec 2025, up 51.07% year-over-year, with the annual reading at -$34.2 million for FY2025, 51.1% up from the prior year.
  • Consolidated Net Income hit -$4.4 million in Q4 2025 for Arbutus Biopharma, up from -$7.7 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $2.5 million in Q2 2025 to a low of -$24.5 million in Q1 2025.
  • Historically, Consolidated Net Income has averaged -$16.1 million across 5 years, with a median of -$17.7 million in 2022.
  • Biggest five-year swings in Consolidated Net Income: plummeted 37.62% in 2021 and later surged 112.64% in 2025.
  • Year by year, Consolidated Net Income stood at -$21.3 million in 2021, then decreased by 2.87% to -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then skyrocketed by 35.28% to -$12.5 million in 2024, then surged by 64.55% to -$4.4 million in 2025.
  • Business Quant data shows Consolidated Net Income for ABUS at -$4.4 million in Q4 2025, -$7.7 million in Q3 2025, and $2.5 million in Q2 2025.